3
Announcements
Trials
Browse
Landscape
Status
Completed
28
Terminated
9
Unknown
6
Active not recruiting
3
Recruiting
2
Withdrawn
1
Suspended
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
4
Sarcoma
2
Myeloid
2
Gastrointestinal
2
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Cyclophosphamide
30
Rituximab
23
zanubrutinib
18
fludarabine
14
Vincristine
14
venetoclax
13
Prednisone
13
blinatumomab
12
Magnetic Resonance Spectroscopy
12
Specimen Handling
11
Doxorubicin
11
obinutuzumab
10
Bendamustine Hydrochloride
10
Lenalidomide
9
Dexamethasone
8
polatuzumab vedotin
7
glofitamab
7
Methotrexate
7
Radiotherapy
6
Prednisolone
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Cytarabine
6
Biopsy
6
pirtobrutinib
5
pegaspargase
5
Immunotherapy, Adoptive
5
tislelizumab
4
tafasitamab
4
selinexor
4
orelabrutinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Imatinib Mesylate
×
Lymphoid
×
Clear all
NCT06175702
2023-12-19
LALPh2022
PETHEMA Foundation
Not yet recruiting
150 enrolled